GlassScriptPhysician profile
Danielle Heather Page
NPI 1497429302
$6,620.29
in general payments reported to CMS, 2019-2025
25 companies · $1,879 in 2025
The $1,879 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.25 · 2022: $736 · 2023: $2,144 · 2024: $1,782 · 2025: $1,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,740 · Education: $65.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,740.08 |
| Education | $65.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,424.37 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $1,103.33 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,069.25 | 2022-2025 | Dupixent |
| Genentech USA, INC. | $558.37 | 2022-2025 | Xolair |
| Optinose US, INC. | $377.83 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $322.77 | 2022-2025 | Takhzyro |
| Grifols USA, LLC | $308.43 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Leo Pharma INC. | $179.40 | 2023-2025 | Adbry, Anzupgo |
| Ars Pharmaceuticals Operations, INC. | $148.16 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $134.68 | 2022-2025 | Tezspire, Airsupra |
| Csl Behring | $130.51 | 2023-2025 | Haegarda, Hizentra |
| Hikma Pharmaceuticals USA | $126.88 | 2023-2025 | Ryaltris |
| Alk-Abello, INC | $96.47 | 2022-2025 | Ragwitek, Odactra, Grastek |
| Novartis Pharmaceuticals Corporation | $95.66 | 2025 | |
| Kaleo, INC. | $94.91 | 2021-2024 | Auvi-Q |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $74.89 | 2023-2024 | Immunocap |
| Amgen INC. | $67.90 | 2025 | Tezspire |
| Pfizer INC. | $55.56 | 2024 | |
| Lilly USA, LLC | $52.30 | 2024-2025 | Ebglyss |
| Incyte Corporation | $49.29 | 2023-2024 | Opzelura |
| Pharming Healthcare, INC. | $43.85 | 2025 | Ruconest |
| Covis Pharma Gmbh | $34.22 | 2022 | |
| Nestle Healthcare Nutrition INC. | $24.97 | 2023 | |
| Octapharma USA, INC. | $24.00 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $22.29 | 2023 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Page listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.